Green Cross Corp
006280
Company Profile
Business description
Green Cross Corp is one of the global leaders in the healthcare sector. The Montreal-based biopharmaceutical company primarily develops intravenous immunoglobulin (IVIG), a key therapeutic solution for the treatment of patients with infectious and immune diseases, and albumin, used as a blood-volumizing agent and in the treatment of burns. Currently, the company has a global presence through its association with various subsidiaries.
Contact
303 Bojeong-Dong
Giheung-Gu
YonginGyeonggi449-070
KORT: +82 312609300
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
2,276
Stocks News & Analysis
stocks
10 of the cheapest global companies with wide moats
These undervalued stocks of high-quality companies could be attractive investments today.
stocks
Bookworm: Buy and hold inspiration from an unlikely source
Ben Graham was the king of flipping deep value stocks. The best investment of his life came from something very different.
stocks
3 ASX shares to avoid
These shares have surged in price in the last year but are significantly overvalued according to our analysts.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,069.00 | 55.70 | 0.70% |
| CAC 40 | 8,028.28 | 90.07 | 1.13% |
| DAX 40 | 22,567.14 | 109.27 | -0.48% |
| Dow JONES (US) | 41,488.19 | 674.62 | 1.65% |
| FTSE 100 | 8,632.33 | 89.77 | 1.05% |
| HKSE | 24,085.92 | 125.94 | 0.53% |
| NASDAQ | 17,303.01 | 345.44 | -1.96% |
| Nikkei 225 | 37,442.28 | 389.18 | 1.05% |
| NZX 50 Index | 12,248.60 | 17.65 | -0.14% |
| S&P 500 | 5,638.94 | 117.42 | 2.13% |
| S&P/ASX 200 | 7,838.30 | 48.60 | 0.62% |
| SSE Composite Index | 3,425.00 | 5.44 | 0.16% |